INCOME TAXES (Details) (USD $)	4 Months Ended	12 Months Ended
	Dec. 31, 2012	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2010
Income Before Taxes [Abstract]
Domestic	$ 12,510,000	$ 26,642,000	$ 37,415,000	$ 18,779,000
Foreign	6,782,000	12,002,000	(220,000)	149,000
Loss before income taxes	19,292,000	38,644,000	37,195,000	18,928,000
Provision for income tax and effective tax rate reconciliation [Abstract]
Federal tax (benefit) at statutory rate	(6,536,000)	(13,111,000)	(12,679,000)	(6,391,000)
State tax (benefit) at statutory rate, net of federal tax benefit	(715,000)	(1,069,000)	(2,247,000)	(953,000)
Change in valuation allowance	2,349,000	4,775,000	19,278,000	6,068,000
Research and development credits	0	(1,034,000)	(1,831,000)	(708,000)
Fair market value of warrants	505,000	1,079,000	5,543,000	2,004,000
Qualified Therapeutic Discovery Project Grant income	0	0	(297,000)	0
Intangible asset basis allocation	1,670,000	2,952,000	(8,633,000)	(20,000)
Stock based compensation - ISO	755,000	1,525,000	493,000	2,000
Foreign losses not benefited	1,995,000	3,848,000	0	0
Other	(23,000)	1,035,000	373,000	(2,000)
Provision for income taxes	0	0	0	0
Federal tax (benefit) at statutory rate (in hundredths)	(34.00%)	(34.00%)	(34.00%)	(34.00%)
State tax (benefit) at statutory rate, net of federal tax benefit (in hundredths)	(3.72%)	(2.77%)	(6.03%)	(5.07%)
Change in valuation allowance (in hundredths)	12.22%	12.38%	51.70%	32.28%
Research and development credits (in hundredths)	0.00%	(2.68%)	(4.91%)	(3.77%)
Fair market value of warrants (in hundredths)	2.62%	2.80%	14.86%	10.66%
Qualified Therapeutic Discovery Project Grant income (in hundredths)	0.00%	0.00%	(0.80%)	0.00%
Intangible asset basis allocation (in hundredths)	8.69%	7.66%	(23.15%)	(0.11%)
Stock based compensation - ISO (in hundredths)	3.93%	3.95%	1.32%	0.01%
Foreign losses not benefited (in hundredths)	10.38%	9.98%	0.00%	0.00%
Other (in hundredths)	(0.12%)	2.68%	1.01%	0.00%
Provision for income taxes (in hundredths)	0.00%	0.00%	0.00%	0.00%
Deferred tax assets [Abstract]
Net operating loss carryforwards	19,514,000	18,075,000	14,940,000	9,155,000
Capitalized start-up costs	11,160,000	8,946,000	6,636,000	3,487,000
Stock option expense	425,000	462,000	462,000	268,000
Research credit	7,970,000	7,873,000	6,275,000	3,513,000
Fixed assets and intangible assets	3,786,000	5,766,000	7,560,000	56,000
Accruals	330,000	105,000	138,000	217,000
Other	(50,000)	(441,000)	0	37,000
Deferred tax assets	43,135,000	40,786,000	36,011,000	16,733,000
Valuation allowance	(43,135,000)	(40,786,000)	(36,011,000)	(16,733,000)
Deferred tax assets, net	0	0	0	0
Operating Loss Carryforwards [Line Items]
Expiration date for operating loss carryforwards	The federal credits expire beginning after the fiscal year ended 2026 and the state credits have no expiration.
Additional tax credits	4,700,000
Federal credits expire beginning	The federal credits expire beginning after the fiscal year ended 2026 and the state credits have no expiration.
Valuation allowance increase	2,349,000	4,775,000	19,278,000	6,068,000
Accrued interest and penalties related to uncertain tax positions	0
Unrecognized tax benefits	0
Liability related to uncertain tax positions	0
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	45,000,000
Expiration date for operating loss carryforwards	2022
Research and development credits	7,500,000
Federal credits expire beginning	2022
Net operating loss carryforwards attributable to stock option	400,000
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	63,100,000
Expiration date for operating loss carryforwards	2016
Research and development credits	700,000
Federal credits expire beginning	2016
Net operating loss carryforwards attributable to stock option	$ 0